The proposed merger of Sequent Scientific and Viyash Life Sciences, backed by Carlyle, has received overwhelming shareholder support. This ₹8,000-crore merger aims to create a global entity, combining Sequent’s animal health focus with Viyash’s human health expertise. Hari Babu Bodepudi, the proposed group CEO, highlights opportunities in animal health generics and leveraging synergies between the companies’ manufacturing capabilities.
​The proposed merger of Sequent Scientific and Viyash Life Sciences, backed by Carlyle, has received overwhelming shareholder support. This ₹8,000-crore merger aims to create a global entity, combining Sequent’s animal health focus with Viyash’s human health expertise. Hari Babu Bodepudi, the proposed group CEO, highlights opportunities in animal health generics and leveraging synergies between the companies’ manufacturing capabilities. by Soban News (international And National News)
